Imavita is investing in its own R&D in the following subjects:
- Cancer cell tracking using FMT (Fluorescence Tomography)
- T-cells tracking using FMT (Fluorescence Tomography)
- Optical Coherence Tomography (OCT) in dermatology models (Atopic Dermatitis / Acne / Psoriasis)
- Inflammation markers using FMT (Fluorescence Tomography)
- Pharmacokinetics of endogenous / exogenous labelled compounds by SPECT/CT and MRS
- Quantitative evaluation of biodistribution & PK parameters using FMT (Fluorescence Tomography)
- MRI/MRS of pre-clinical models of neurodegenerative models
- Atherosclerosis imaging in preclinical models using FMT (Fluorescence Tomography)
- Inflammation imaging in arthritis models using FMT (Fluorescence Tomography)
Research Tax Credit
Imavita has Research Tax Credit agreement / CIR (“Crédit Impôt Recherche“) for years 2016 to 2020 (obtained on April 22th 2016 / download pdf file of Research Tax Credit Accreditation).
This agreement, obtained from the french authorities, permits to the clients working with Imavita to refund R&D spendings to their corporate taxes.
See the following links for more informations on CIR / Research Tax Credit: MESR (Ministère de l’Enseignement Supérieur et de la Recherche).
Summary on Research Tax Credit
All companies incurring R&D expenses are eligible to receive France’s research tax credit, regardless of their size, business sector and nationality.
The tax credit covers 30% of all R&D expenses and covers all R&D spending: Salaries, social security contributions, amortization and depreciation allowances, operating costs, subcontracting, patents and monitoring.
The scope of SME spending eligible for the research tax credit has been extended as of 2013 to cover innovation expenses arising from designing prototypes, as well as pilot plants for new products. These expenses are now included in the research tax credit base, at a rate of 20%.